@article{71e3266ec52c4cd9b5fbc09f9aff8893,
title = "Resting-state EEG for the diagnosis of idiopathic epilepsy and psychogenic nonepileptic seizures: A systematic review",
abstract = "Quantitative markers extracted from resting-state electroencephalogram (EEG) reveal subtle neurophysiological dynamics which may provide useful information to support the diagnosis of seizure disorders. We performed a systematic review to summarize evidence on markers extracted from interictal, visually normal resting-state EEG in adults with idiopathic epilepsy or psychogenic nonepileptic seizures (PNES). Studies were selected from 5 databases and evaluated using the Quality Assessment of Diagnostic Accuracy Studies-2. 26 studies were identified, 19 focusing on people with epilepsy, 6 on people with PNES, and one comparing epilepsy and PNES directly. Results suggest that oscillations along the theta frequency (4–8 Hz) may have a relevant role in idiopathic epilepsy, whereas in PNES there was no evident trend. However, studies were subject to a number of methodological limitations potentially introducing bias. There was often a lack of appropriate reporting and high heterogeneity. Results were not appropriate for quantitative synthesis. We identify and discuss the challenges that must be addressed for valid resting-state EEG markers of epilepsy and PNES to be developed.",
keywords = "Systematic review, Epilepsy, Psychogenic nonepileptic seizures, Resting-state EEG, Diagnostic marker, Theta rhythm",
author = "Irene Faiman and Stuart Smith and John Hodsoll and Allan Young and Paul Shotbolt",
note = "Funding Information: This work was supported by the Bergqvist Charitable Trust through the Psychiatry Research Trust as a PhD scholarship to Irene Faiman. Professor Young{\textquoteright}s independent research is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King{\textquoteright}s College London . The views expressed are those of the authors and not necessarily those of the funding Trusts, the NHS, the NIHR, or the Department of Health. The funders were not involved in any aspects of this work{\textquoteright}s planning, execution, or article preparation. Funding Information: This work was supported by the Bergqvist Charitable Trust through the Psychiatry Research Trust as a PhD scholarship to Irene Faiman. Professor Young's independent research is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King's College London. The views expressed are those of the authors and not necessarily those of the funding Trusts, the NHS, the NIHR, or the Department of Health. The funders were not involved in any aspects of this work's planning, execution, or article preparation. Funding Information: We would like to acknowledge the Bergqvist Charitable Trust and the Psychiatry Research Trust for their financial support. Professor Young's independent research is funded by the National Institute for Health Research (NIHR) Biomedical Research Centre at South London and Maudsley NHS Foundation Trust and King{\textquoteright}s College London. Funding Information: Declarations of interest for Allan H. Young: Employed by King{\textquoteright}s College London; Honorary Consultant SLaM (NHS UK). Paid lectures and advisory boards for the following companies with drugs used in affective and related disorders: Astrazenaca, Eli Lilly, Lundbeck, Sunovion, Servier, Livanova, Janssen, Allegan, Bionomics, Sumitomo Dainippon Pharma, COMPASS. Consultant to Johnson & Johnson. Consultant to Livanova. Received honoraria for attending advisory boards and presenting talks at meetings organised by LivaNova. Principal Investigator in the Restore-Life VNS registry study funded by LivaNova. Principal Investigator on ESKETINTRD3004: “An Open-label, Long-term, Safety and Efficacy Study of Intranasal Esketamine in Treatment-resistant Depression.” Principal Investigator on “The Effects of Psilocybin on Cognitive Function in Healthy Participants”. Principal Investigator on “The Safety and Efficacy of Psilocybin in Participants with Treatment-Resistant Depression (P-TRD)”. Grant funding (past and present): NIMH (USA); CIHR (Canada); NARSAD (USA); Stanley Medical Research Institute (USA); MRC (UK); Wellcome Trust (UK); Royal College of Physicians (Edin); BMA (UK); UBC-VGH Foundation (Canada); WEDC (Canada); CCS Depression Research Fund (Canada); MSFHR (Canada); NIHR (UK). Janssen (UK). No shareholdings in pharmaceutical companies. Publisher Copyright: {\textcopyright} 2021 The Author(s) Copyright: Copyright 2021 Elsevier B.V., All rights reserved.",
year = "2021",
month = aug,
doi = "10.1016/j.yebeh.2021.108047",
language = "English",
volume = "121",
journal = "Epilepsy & Behavior",
issn = "1525-5050",
publisher = "ACADEMIC PRESS INC",
number = "Part A",
}